AUTHORS
Nicholas Short, MD, Stephen A. Strickland, MD2, David Berz, MD, PhD, MPH3, Anthony Selwyn Stein, MD4, Michael Maris, MD5, Debashree Das, PhD6, Allan Kaspar, PhD7, Brian Kaspar, PhD8, Samit Varma9, Mary May10, Gina Giannantoni11, Jacob Scott, MD, DPhil, DABR12, Allen Reha13, Timothy Peter Cripe, MD, PhD14
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Sarah Cannon Research Institute, Nashville, Tennessee, United States
3 Valkyrie Clinical Trials, Los Angeles, California, United States
4 City of Hope, Duarte, California, United States
5 Colorado Blood Cancer Institute, Denver, Colorado, United States
6 Vironexis Biotherapeutics, Inc., San Diego, California, United States
7 Vironexis Biotherapeutics, Inc., San Diego, California, United States
8 Vironexis Biotherapeutics, Inc., San Diego, California, United States
9 Vironexis Biotherapeutics, Inc., San Diego, California, United States
10 Vironexis Biotherapeutics, Inc., San Diego, California, United States
11 Vironexis Biotherapeutics, Inc., San Diego, California, United States
12 Cleveland Clinic Foundation, Cleveland, Ohio, United States
13 Vironexis Biotherapeutics, Inc., San Diego, California, United States
14 Nationwide Children's Hospital, Columbus, Ohio, United States
ABSTRACT
Background: CAR-T cells and bispecific T-cell engagers (bi-TCE) have transformed the treatment of CD19-positive B cell malignancies including relapsed/refractory (R/R) B-cell lymphomas and acute lymphoblastic leukemia (B-ALL), but limitations remain. CAR-T requires individualized manufacturing, lymphodepletion, and specialized centers, while blinatumomab, a CD19 bi-TCE with levels up to 3.7 ng/mL at its MTD, requires continuous intravenous infusion to achieve steady state levels. Hence, strategies are being heavily pursued to develop single-dose, off-the-shelf in vivo CAR-T. As an alternative, we developed VNX-101, a single-dose adeno-associated virus (AAV)-based CD19-targeted T-cell engager gene therapy, utilizing an in vivo protein engineering approach. VNX-101 was designed to transduce hepatocytes following a single-dose and drive long-term systemic expression of GP101, a secreted CD19 bi-TCE.
Methods: SENTRY-CD19 is an ongoing Phase 1/2 safety, dose-finding, and PK study in patients with R/R CD19-positive hematologic malignancies (NCT06533579). Part 1 evaluates single-dose IV VNX-101 in adults to identify a RP2D based on safety, DLTs during an 8-week observation period, serum GP101 levels, and antitumor activity.
Results: Nine subjects have been dosed, 2 recently treated subjects (ALL and CLL) have limited follow-up, with GP101 and response assessments pending. Among the 7 subjects with evaluable follow-up, 4 had no measurable serum GP101: 3 treated at 1.0E11 vg/kg and 1 with follicular lymphoma treated at 1.95E11 vg/kg. These subjects had detectable pre-existing anti-AAVrh74 antibodies (titers 1:50–1:200), which may have limited transduction. None experienced CRS or ICANS; the 3 subjects treated at 1.0E11 vg/kg also had no B-cell aplasia. In contrast, the remaining 3 subjects had baseline anti-AAVrh74 titers <1:50 and measurable GP101. One subject with rapidly progressive DLBCL received 3.0E11 vg/kg, reached a peak GP101 concentration of 26.6 ng/mL, and experienced grade 3 mental status change (grade 2 ICANS); he subsequently discontinued due to disease progression. The other 2 subjects had multiply relapsed/refractory B-cell ALL and received 2.4E11 vg/kg, achieved MRD-negative remission, and are described in detail below.
The first patient is a 53-year-old male with B-ALL who had received six prior lines of therapy including chemotherapy, blinatumomab, allogeneic stem cell transplant, inotuzumab ozogamicin, and CD19 CAR-T. He presented with bone marrow relapse and multicompartment FDG-avid extramedullary disease (EMD). Following VNX-101, he achieved MRD-negative marrow by ClonoSEQ at Day 28, with complete resolution of all EMD sites on FDG-PET/CT by Day 54 and sustained complete response through Day 84. His GP101 peak was 1.38 ng/mL, within the blinatumomab therapeutic window. He did not have CRS, but did experience short-lived grade 2 ICANS managed with steroids and intrathecal chemotherapy. He subsequently received additional maintenance chemotherapy as a bridge to stem cell transplant while still in continuous PET and ClonoSEQ negative remission.
The second patient is a 31-year-old male with B-ALL who had received four prior lines of therapy including chemotherapy, blinatumomab (refractory), inotuzumab ozogamicin, and CD19 CAR-T. His marrow showed >90% blasts. Following VNX-101, he achieved MRD-negative marrow by ClonoSEQ at Day 28, with CD19+ B-cell depletion and ClonoSEQ negativity sustained through the most recent assessment at Month 4. Although he also did not have CRS, he experienced a single-episode Grade 4 ICANS seizure at Day 6, consistent with his high leukemic burden and peak GP101 of 13 ng/mL, that was designated a DLT; it resolved completely by Day 14 following treatment with high-dose corticosteroids, levetiracetam, and anakinra and has not recurred.
Summary/Conclusion: In SENTRY-CD19, single-dose novel gene therapy produced circulating GP101, on-target B-cell depletion, and rapid and sustained antileukemic activity in two heavily pretreated patients with R/R B-ALL. To our knowledge, these are the first two clinical examples of antitumor efficacy following systemic AAV-mediated delivery of a therapeutic protein in oncology. The study is ongoing to explore lower dose levels in patients without pre-existing anti-AAV antibodies, along with measures to mitigate neurotoxicity including prophylactic steroids and anti-seizure medications as well as heightened safety monitoring.
DISCLOSURES
Nicholas Short, MD: Sanofi - Honoraria; Astellas Pharma Inc - Honoraria; Pfizer Inc - Honoraria; BeiGene - Honoraria; AstraZeneca - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Takeda - Honoraria; Merck - Honoraria; Adaptive Biotechnologies - Honoraria; Xencor - Research Funding; Hemogenyx - Research Funding; Astellas Pharma Inc - Research Funding; Takeda - Research Funding; Nexcure - Research Funding; Remedy Plan - Research Funding; NextCure - Research Funding; Vironexis - Research Funding; Takeda Oncology - Research Funding; GSK - Research Funding; Stemline Therapeutics - Research Funding; Novartis - Research Funding; Ascentage - Research Funding; Honoraria - Research Funding; Pfizer Inc - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); AB Science - Consultancy (Includes expert testimony); NKARTA - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)